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Abstract 
The concept that G protein-coupled receptors can exist as homo- and/or hetero-meric 
complexes is now well established. Despite this, how dynamic such interactions are 
and if this may be modulated during receptor trafficking remain topics of debate. Use 
of endoplasmic reticulum trapping strategies and the generation of asymmetric homo-
mers have started to provide information on the contribution of protein-protein 
interactions to receptor maturation, cell surface delivery and ligand-mediated 
endocytosis. Although dimer/oligomer formation appears to be essential for cell 
surface delivery of class A and class C GPCRs, this may not be the case for class B 
receptors. 
 
Abbreviations 
BRET, bioluminescence resonance energy transfer; CFP, cyan fluorescent protein; 
ER, endoplasmic reticulum; FRET, fluorescence resonance energy transfer; GPCR, G 
protein-coupled receptors; TMD, transmembrane domain; YFP, yellow fluorescent 
protein; 
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 Introduction 
Following reconstitution of single, purified monomeric class A G protein-coupled 
receptors (GPCRs) into high-density lipoprotein phospholipid bilayer particles agonist 
ligands are able to activate added G protein [ 1-2 ]. Although such observations 
demonstrate clearly that monomeric GPCRs are able to initiate canonical, G protein-
mediated signal transduction, and there are suggestions that certain observations 
consistent with GPCR quaternary structure have been over-interpreted [3], substantial 
evidence indicates that GPCRs are able to form and exist as dimers and/or higher-
order oligomers [4-5].  The class C, metabotropic glutamate receptor-like GABAB 
receptor was the first GPCR recognized to require quaternary structure for cell surface 
delivery and function (see [6] for review). The functional GABAB receptor is a 
constitutive hetero-dimer (or possibly a hetero-tetramer [7]) formed by direct 
interactions between the polypeptide products of two distinct, but highly related 
genes.  When expressed alone, the GABABR1 polypeptide is retained in the 
endoplasmic reticulum (ER) due to the presence of an ER-retention sequence in the 
intracellular C-terminal tail.  Co-expression of the GABABR2 polypeptide generates 
protein-protein interactions that result in the retention motif being masked and allows 
cell surface delivery of the hetero-complex. Despite there being no substantial 
sequence conservation between class C GPCRs and members of other GPCR families, 
models that explore the importance of successful pre-assembly of dimers/oligomers in 
the ER have been explored recently for other classes of GPCRs. The proportion of 
GPCR populations that exist as dimeric/oligomeric complexes has also been a topic of 
recent debate, as has whether GPCRs internalize as dimers/oligomers following 
exposure to agonist ligands. These topics will form the basis of the current review. 
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 Where do GPCR dimers/oligomers form? 
Based on understanding the ER assembly of the heteromeric GABAB receptor 
complex Salahpour et al., [8] replaced the C-terminal tail of the rhodopsin-like, class 
A β2-adrenoceptor with the equivalent region of the GABABR1.  This generated a 
form of the β2-adrenoceptor that was trapped inside transfected cells. This construct 
was also able to prevent cell surface delivery of co-expressed wild type β2-
adrenoceptor and retained the wild type receptor in the ER [8].  These observations 
were consistent with the C-terminally modified receptor interacting with the wild type 
receptor but with an inability of wild type β2-adrenoceptor to mask the GABABR1 
ER-retention motif introduced into the modified β2-adrenoceptor. Furthermore, these 
studies also indicated that homo-dimerization of the β2-adrenoceptor was unlikely to 
be governed largely or exclusively by interactions involving the C-terminal tail.  
Although other GPCRs closely related to the β2-adrenoceptor were not tested, cell 
surface delivery of an N-terminally epitope-tagged form of the β2-adrenoceptor was 
substantially higher when co-expressed with the full length GABABR1 polypeptide 
than with the β2-adrenoceptor containing the GABABR1 C-terminal tail and ER-
retention motif [8]. Importantly, bioluminescence resonance energy transfer (BRET) 
studies indicated little interaction between the β2-adrenoceptor and GABABR1 [8], 
consistent with the concept that physical interactions between the wild type and the 
ER-retained, modified form of the β2-adrenoceptor, rather than simply the presence of 
an ER-retained protein, was the basis for poor cell surface delivery of the wild type 
receptor.  This general approach has the potential to be used to explore the selectivity 
and location of GPCR dimerization but is not restricted to use of the GABABR1 C-
terminal ER trapping sequence. A number of other GPCRs, for example the α2C-
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adrenoceptor [9], contain what appear to be arginine-based ER-retention motifs. 
Indeed, transient expression of the α2C-adrenoceptor in HEK293 cells results in a 
pattern of expression consistent with predominant ER retention [9]. After addition of 
this ER-retention motif to the C-terminal tail of the chemokine CXCR1 receptor, 
Wilson et al., [9] noted both that the modified chemokine receptor was unable to 
reach the cell surface and that the ER-trapped CXCR1 receptor was able to limit cell 
surface delivery of co-expressed, wild type CXCR1. Furthermore, the ER-retained 
CXCR1 receptor also prevented cell surface delivery of the closely-related chemokine 
receptor CXCR2 [9], providing a clear example of the generation within the ER of a 
heteromer between closely related class A receptors.  By contrast, co-expression of 
the ER-trapped CXCR1 receptor did not modulate cell surface delivery of the α1A-
adrenoceptor [9].  This was an important control because there are often concerns 
about the specificity of GPCR dimerization, particularly in transient transfection 
studies where it is difficult to define expression levels in individual cells. Because 
parallel saturation BRET studies [10] indicated that CXCR1 generated homomers and 
CXCR1-CXCR2 heteromers with equal efficiency, and also confirmed that the 
CXCR1 receptor did not interact with the α1A-adrenoceptor [9], such studies also 
suggested that the ‘dominant-negative’ effects of the ER-retained receptor to prevent 
surface delivery were correlated with, and might reflect, dimerization potential. Since 
these studies a number of other reports have generated data consistent with physical 
interactions between GPCR monomers being initiated within the ER. For example, an 
ER-retained mutant of the α2B-adrenoceptor is able to cause ER-retention of wild type 
α2B-adrenoceptor [11] as well as of the α2A-and α2C-adrenoceptors [11]. Furthermore, 
introduction of the ER-retained α2B-adrenoceptor mutant into cells that express 
various α2-adrenoceptor subtypes endogenously resulted in reduced cell surface 
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delivery of the endogenous α2-adrenoceptor [11]. Fluorescence resonance energy 
transfer (FRET) measurements performed in cells co-expressing C-terminally cyan 
fluorescent protein (CFP)- and yellow fluorescent protein (YFP)-tagged serotonin 5-
HT2C receptors also identified interactions within the ER and, via time-lapse 
miscoscopy, such complexes were followed through the Golgi apparatus and to the 
plasma membrane [12]. As FRET efficiencies measured in the ER, Golgi, and plasma 
membrane compartments were similar, this suggested that the 5-HT2C receptor 
remained a dimeric or oligomeric complex as it trafficked to the cell surface after 
synthesis [12]. The ability to measure GPCR-GPCR interactions in cell fractions 
isolated from sucrose density and other gradient systems, initially employing time-
resolved FRET measurements [13] and, more recently BRET studies [14], has also 
allowed demonstration of receptor homomers in distinct cellular compartments [13-
14].  Although not providing direct evidence on the location of biogenesis of GPCR 
dimers, such studies have confirmed populations of receptor homomers to co-migrate 
with ER markers, such as the protein-folding chaperone calnexin, as well as plasma 
membrane markers such as the Na+/K+ ATPase [13-14]. Co-localization with calnexin 
and related chaperone proteins is of particular relevance as direct interactions of a 
number of GPCRs with calnexin has been shown [15-16] and relate to the progress of 
receptors from the ER if they are correctly folded.  
It is unclear how, subsequently, variation in identity of the final transport vesicle 
populations for different GPCRs is determined, but a series of elements, often in 
different regions of the receptor sequence, can modulate export from the ER [17-18], 
and in many GPCRs there may be multiple such elements. However, recently, a 
single, highly conserved Leu residue in the first intracellular loop has been suggested 
to play an important role in ER export for a large number of GPCRs, including a 
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range of adrenoceptors and the angiotensin AT1 receptor [19] and mutation of this 
residue may offer a general means to generate ER-retained mutants that could be used 
in the types of studies described above. 
Pathways of cell surface delivery of GPCRs are less well studied than pathways of 
receptor internalization from the cell surface, but despite clear evidence of distinct 
vesicular pools being favoured by individual receptors [18, 20], the early stages of 
ER-quality control involving interactions with ER-resident chaperone proteins, and 
the subsequent processing of N-linked glycosylation, as GPCRs move from the ER to 
the Trans-Golgi Network  are similar to other proteins that are destined to be 
trafficked via the secretory pathway.  These ensure that only properly folded and 
assembled proteins proceed. In this regard it is important to note that it is well 
established that the quaternary structure of many other classes of cell surface 
receptors, such as ion channels and transforming growth factor receptors, as well as 
certain ATP binding cassette transporters, are pre-fabricated into the correct 
quaternary organization before cell surface delivery [21-22]. It is, therefore, hardly 
surprising that this general rule should also apply to GPCRs, and there is growing 
evidence that such quaternary complexes may contain G protein subunits as well the 
GPCR(s) [23].  There have been sporadic reports of the inability to replicate specific 
examples of GPCR heteromerization and, clearly, it is important to examine potential 
reasons for these discrepancies.  For example, although the proclivity of the 
angiotensin AT1 receptor to form heteromers with the bradykinin B2 receptor has 
recently been questioned [24], it has also recently been suggested that the expression 
level of the chaperone protein calreticulin defines the effectiveness of these 
interactions [25] as only the properly folded and fully mature bradykinin B2 receptor 
is reported to interact with the angiotensin AT1 receptor [25]. If this is a general 
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feature, it may be helpful in defining the earliest stages of GPCR heteromer 
generation and, potentially, also homomer formation. In this context it is also 
interesting to note that cell surface delivery of a DOP-MOP opioid receptor heteromer 
can be controlled by a Golgi chaperone named RTP4 [26], potentially via RTP4 
protecting the DOP-MOP heteromer from ubiquitination and degradation [26]. This 
can lead to an increase in surface heteromer levels [26]. 
 
Receptor co-expression can enhance cell surface delivery of GPCRs 
In contrast to the ‘dominant negative’ effects of certain GPCRs and mutants thereof, 
there are also a number of reports, apart from the GABAB receptor, in which co-
expression of a second GPCR promotes cell surface delivery of the GPCR being 
studied [27-28].  For example, a number of adrenoceptor subtypes have been shown 
to both interact with the α1D-adrenoceptor and to promote its cell surface delivery and 
function [28-29]. Although the physiological significance remains unclear, interaction 
with certain GPCRs has also been suggested as a means to promote cell surface 
delivery in heterologous systems of a number of olfactory receptors to allow their 
characterization [30]. Although these examples do not require the co-presence of 
receptor ligands, the concept that cell permeant, small molecule ligands can promote 
cell surface delivery of a number of GPCR mutants by altering their conformation 
such that they can now (by)pass the quality control systems of the ER has been widely 
explored in recent times and such ‘pharmacological chaperones’ [27, 31-32] have 
been discussed widely in terms of their clinical potential. Furthermore, extensions of 
the ability of such ligands to recover the structural organization and trafficking of 
newly synthesized GPCRs have recently been used to provide novel insights into the 
location and relevance of GPCR dimerization. 
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 Do mutations and manipulations that interfere with GPCR dimerization 
modulate ER release and cell surface trafficking?  
Many GPCRs that are associated with disease lack function because they fail to pass 
ER export quality control and reach the cell surface [31-35], rather than being 
inherently unable to bind ligands and generate signals.  This lack of cell surface 
delivery results in the protein being routed for degradation. In many cases such 
mutants can also act as ‘dominant-negatives’ as they also prevent the cell surface 
delivery of a co-expressed wild type form of the GPCR and, in physiological settings, 
this can account for function being reduced by more than the anticipated 50% in 
individuals heterozygous for the mutation.  For example, for the class C Ca2+ sensing 
receptor a series of mutants including Arg66His and Arg66Cys, that are associated with 
familial hypocalciuric hypercalcemia/neonatal severe hyperparathyroidism, lack 
mature glycosylation, and are localized within the ER but not within the Golgi 
apparatus [34]. Photo-bleaching FRET microscopy showed that these mutants, as well 
as the wild type receptor were dimerized in the ER [34]. Equally, a number of mutants 
of the melanocortin 1 receptor are retained intracellularly and have ‘dominant 
negative’ effects on the function of the wild type receptor [35]. However, although it 
remains to be investigated fully, it is unlikely that many of these or related mutations 
are located directly at key GPCR dimeric interfaces (see next paragraph). Despite this, 
if GPCR mutants that are limited in their ability to dimerize are ER-retained they may 
be useful in understanding some aspects of the role of dimerization in GPCR 
assembly. 
Canals et al., [36] took advantage of the disrupted oligomeric organization of an α1B-
adrenoceptor that contains pairs of point mutations in transmembrane domains (TMD) 
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I and IV. This mutant was ER-retained when expressed either transiently [37] or 
stably [36] in HEK293 cells and prevented cell-surface delivery of co-expressed wild 
type α1B-adrenoceptor [36-37].  Although mutated at 4 positions the modified α1B-
adrenoceptor clearly retained core structure because it was able to bind α1-
adrenoceptor ligands, such as [3H]prazosin, with affinity akin to the wild type receptor 
[36-37] and, although ER-retained, did retain some capacity to generate oligomeric 
contacts because expression of pairs of this mutant that were C-terminally tagged with 
bi-molecular fluorescence complementation-competent fragments of YFP [38], 
resulted in generation of an ER-restricted fluorescent signal [37]. However, sequential 
three-colour FRET measurements indicated that the detailed organizational quaternary 
structure of the mutant was different from wild type 1B-adrenoceptor [37].  The TMD 
mutant α1B-adrenoceptor was transported to the surface in cells that were exposed to 
prazosin and other ligands with affinity for the α1B-adrenoceptor  [36-37] and in the 
presence of such a ‘pharmacological chaperone’ the quaternary structure of the TMD 
mutant α1B-adrenoceptor, monitored by 3 colour FRET,  was restored to something 
akin to that of wild type α1B-adrenoceptor [37]. Interestingly, prazosin is not a highly 
cell permeant ligand and the EC50 to promote cell surface delivery of the TMD mutant 
α1B-adrenoceptor was some 50-100 fold higher than the Kd for binding in broken cell 
preparations [36-37]. This was interpreted as indicating the poor access of prazosin to 
the ER-retained receptor as the ligand would be required to equilibrate across not only 
the plasma membrane but the ER membrane as well. The studies indicated that 
binding of an appropriate ligand was able to either assist folding and/or engender a 
conformational alteration that enhanced dimerization.  To assess if the 
pharmacological chaperone caused cell surface delivery of a quaternary homomeric 
complex rather than simply monomers of the α1B-adrenoceptor, Canals et al., [36] 
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also generated a mutant α1B-adrenoceptor that was unable to bind prazosin. This 
mutant Asp125Ala α1B-adrenoceptor, as for the wild type receptor, was both 
successfully delivered to the cell surface when expressed in isolation in HEK293 cells 
and became ER-trapped when co-expressed with the TMD mutant α1B-adrenoceptor 
[36]. Importantly, addition of prazosin to cells co-expressing Asp125Ala α1B-
adrenoceptor and the TMD mutant α1B-adrenoceptor resulted in their co-delivery to 
the cell surface [36]. As a further control, addition of the Asp125Ala mutation into the 
TMD mutant α1B-adrenoceptor generated a form of the receptor that was retained in 
the ER when expressed but which could not be recovered and trafficked to the cell 
surface by prazosin or other ligands with α1B-adrenoceptor affinity, demonstrating 
that interaction of the pharmacological chaperone at the orthosteric binding site was 
required.   As the Asp125Ala α1B-adrenoceptor cannot bind ligands, the results of the 
co-expression studies indicated that it must have been carried to the cell surface in a 
homomeric complex with the TMD mutant α1B-adrenoceptor [36]. Previous studies 
had shown that the α1B-adrenoceptor exists as an oligomer rather than a strict dimer 
[37]. However, these trafficking studies were not appropriate to usefully define 
whether the overall size of the complex changed in response to binding of the 
antagonist chaperone ligand, as has recently been suggested for the muscarinic M1 
acetylcholine receptor upon binding of the antagonist pirenzepine [39].  
In support of a model in which receptor homomers are pre-assembled in the ER and 
trafficked subsequently to the cell surface, Kobayashi et al., [40] noted that mutation 
of residue Val 179 of the β1-adrenoceptor (position 4.46 in the Ballesteros and 
Weinstein nomenclature, in which the most conserved amino acid in each 
transmembrane domain across the class A GPCR family is designated X.50 and other 
amino acids are then related to this position based on the primary amino acid 
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sequence.  Hence in TMD 4 of the β1-adrenoceptor the Trp residue at position 183 in 
the primary sequence is residue 4.50 and residue 179 is 4 amino acids earlier in the 
primary sequence) or of  Trp 183 (position 4.50) resulted in intracellular retention of 
the modified receptor.  In both cases, cell surface delivery was enhanced by treatment 
of cells with antagonists, such as alprenolol, that bind the β1-adrenoceptor. The Val 
179 and Trp 183 mutants also displayed increased BRET50 values in ‘saturation’ 
BRET [10] studies designed to explore the avidity of protein-protein interactions, 
consistent with a reduced interaction affinity and propensity to dimerize. The BRET50 
value for Trp183Alaβ1-adrenoceptor was reduced to close to the value observed for the 
wild type β1-adrenoceptor following treatment of cells with alprenolol, but whilst the 
EC50 for alprenolol was considerably greater than the anticipated Kd at the wild type 
β1-adrenoceptor,  direct estimates of the affinity of ligands for the mutated receptor 
were not reported. Despite this, these studies are entirely consistent with a model in 
which correct interactions to generate an appropriately folded receptor homomer are 
required for the receptor to be allowed to traffic to the cell surface. In a rather 
different, but conceptually related approach, Kong et al., [41] demonstrated that 
although when expressed individually, both the wild type dopamine D1 receptor and 
an Asp103Ala mutant that is anticipated to be unable to bind catecholamine ligands, 
were delivered to the cell surface,  their co-expression resulted in intracellular 
trapping of both. The asymmetric homomer so produced could be recovered to the 
cell surface only with the use of cell-permeant agonists and not antagonists [41], 
suggesting that a conformational change associated with receptor activation was 
required to generate trafficking-competent quaternary structure. Few studies have 
attempted to define whether the overall molecular organisation of GPCRs alters 
during trafficking from ER/Golgi to the cell surface but Vidi et al., [42] have used 
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combinations of bi-molecular fluorescence complementation and FRET to explore 
this issue for the adenosine A2a receptor, concluding that dimers may be trafficked 
from the ER to the plasma membrane with subsequent higher-order oligomerization 
occurring at the plasma membrane. These are challenging experiments, not least 
because the essentially irreversible formation of the bi-molecular fluorescence 
complementation signal defines that interactions identified in this way are likely to 
remain at least in the dimeric state, and further work is required to explore this topic.  
It is of considerable interest that in the studies of both Canals et al., [36] and 
Kobayashi et al., [40] mutation of amino acids within TMD IV resulted in ER-
trapping, and inefficient, but not elimination of,  homomerization. Although other 
regions of GPCRs have been implicated as being dimer interfaces (see [4] for review), 
many recent studies have indicated elements of TMD IV to be important for homo-
dimeric interactions [37, 43-44]. It is further of interest that in the β1-adrenoceptor 
one of these amino acids is the Trp residue that is the most highly conserved residue 
in TMD IV and, therefore, must play an important role because it is so highly 
conserved in class A GPCRs. However, at least in the adenosine A1 receptor, 
mutation of this residue to Ala does not alter homomer formation or cellular 
trafficking [45]. As such, a general role for this residue in dimerization remains 
unproven and probably unlikely.  Moreover, in a number of X-ray structures of 
GPCRs a molecule of cholesterol is bound at this location (see [46] for review) and 
the implications of this for GPCR quaternary structure are unclear. Furthermore, it is 
even more difficult to extrapolate predictions to GPCR heteromers. For example, 
although TMD IV mutations modulated homo-dimerization of the β1-adrenoceptor 
they did not alter interactions between the β1-adrenoceptor and the β2-adrenoceptor 
[40]. 
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Because single (and even the combination of multiple) point mutants have failed to 
result in the generation of GPCRs that are obvious monomers, other approaches have 
been used to try to interfere with GPCR dimerization and hence to define its 
relevance. For example, addition of peptides that correspond to individual TMDs of 
GPCRs have been used both in intact cell and membrane-based studies. For the 
chemokine CXCR4 receptor a synthetic peptide corresponding to TMD IV reduced 
oligomerization as reported by a reduction of FRET signals in cells co-expressing 
CFP and YFP- tagged forms of the receptor. It also inhibited ligand-induced actin 
polymerization, and blocked chemotaxis of malignant cells [47]. These results have 
been interpreted as evidence for specific functional roles of CXCR4 dimers and build 
on other studies that have attempted to disrupt chemokine receptor homo- and hetero- 
mers (see [47-48] for details). 
Although many fewer studies have examined homomer and heteromer formation for 
the class B receptor family, there is good evidence for such interactions (see [49] for 
review). Although there is no sequence similarity between class B and class A 
GPCRs, at least for the class B secretin receptor, TMD IV again appears to be a key 
element in allowing production of the homomer [50], but unlike many class A 
receptors, to date there is no evidence to support the formation of higher order 
multimers [51]. It remains to be established if this will be the pattern for other class B 
receptors and evidence suggests that this may vary between different class C GPCRs. 
Here the GABAB receptor can exist as at least a tetramer, whilst for metabotropic 
glutamate receptors only strict dimers have been detected [7]. Interestingly, by using a 
peptide corresponding to TMD IV of the secretin receptor Gao et al., [52] were able to 
apparently monomerize this receptor and this was associated with lack of high 
affinity, guanine nucleotide-sensitive binding of agonist ligand. These observations 
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are at least consistent with the secretin receptor dimer being required for G protein 
binding [52], whilst monomeric class A GPCRs are sufficient to produce such 
pharmacology and function [1-3]. A further element that may be different between 
class B and class A receptors is that following secretin receptor dimer disruption 
produced by the TMD IV peptide, the apparently monomeric receptor and various 
TMD IV point mutants were still able to traffic to the surface of cells [52].  
 
Do GPCRs internalize as dimers? 
Once at the cell surface many GPCRs become internalized via endocytosis, either 
spontaneously or in response to the binding of agonist ligands. This topic has been 
reviewed extensively and is beyond the scope and capacity of this article. However, 
the physical organization of internalized GPCRs, and if their oligomeric status is 
altered during this process, has been the subject of considerable debate. The capacity 
of a selective ligand of one GPCR to cause internalization of both its cognate GPCR 
and a second co-expressed GPCR has been used as evidence to favor the presence and 
internalization of intact GPCR heteromers (see [4] for review). This is more 
challenging to approach, however, for GPCR homomers.  A developing strategy in 
this area is to generate asymmetric homomers following co-expression of a wild type 
GPCR and a variant of the GPCR that is unable to bind and respond to the same 
ligand(s) as the wild type receptor. For GPCRs with catecholamine ligands this can be 
achieved simply by alteration of the Asp residue at position 3.32 that is required to 
provide high affinity interaction with the amine headgroup of the ligand. Furthermore, 
in a limited number of cases ligands able to act as agonists at such mutated receptors 
but not at the corresponding wild type receptor have been synthesized. In the case of 
the β2 -adrenoceptor, regulated co-expression of a wild type and an Asp3.32Ser 
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mutant resulted in co-internalization of both forms of the receptor in response to 
isoprenaline, despite the mutant having no significant affinity for this ligand and not 
being internalized upon addition of isoprenaline when expressed in the absence of 
wild type β2  adrenoceptor [53]. Furthermore, a synthetic ligand that is a full agonist at 
the mutant receptor but has little affinity for the wild type also caused co-
internalization of both forms of the receptor [53]. This basic approach requires to be 
extended to other GPCRs to test the generality of these observations and the 
expanding range of GPCRs for which variants that are activated solely by synthetic 
ligands are available offers a means to do so. 
These range of approaches utilized in the studies discussed in this review are starting 
to unravel the basis and importance of GPCR-GPCR interactions in receptor synthesis 
and cell surface trafficking. As with other aspects of the importance of GPCR 
dimerization, key studies need to be translated to physiologically relevant cells and 
tissues before clear understanding will be achieved. 
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